NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

PAVM

PAVmed Inc

Jul 09 • 04:00PM ET

0.5987

Dollar change +0.0444
Percentage change 8.01	%

Healthcare • Medical Devices • USA • NASD

Peers: AVGR ICAD NUWE MLSS SINT BMTX RVP AXGN BLFS SMLR

| Held by: VXF

Scroll to Statements

Index	-	P/E	0.85	EPS (ttm)	0.71	Insider Own	19.13%	Shs Outstand	16.77M	Perf Week	-2.82%
Market Cap	10.35M	Forward P/E	-	EPS next Y	-0.44	Insider Trans	0.00%	Shs Float	13.99M	Perf Month	-5.24%
Enterprise Value	39.11M	PEG	-	EPS next Q	-0.13	Inst Own	7.18%	Short Float	2.32%	Perf Quarter	-0.22%
Income	72.45M	P/S	5.20	EPS this Y	-95.62%	Inst Trans	1.37%	Short Ratio	2.09	Perf Half Y	-11.04%
Sales	1.99M	P/B	0.54	EPS next Y	-344.44%	ROA	164.24%	Short Interest	0.32M	Perf YTD	-4.59%
Book/sh	1.12	P/C	3.83	EPS next 5Y	-	ROE	-	52W High	1.90 -68.49%	Perf Year	-15.44%
Cash/sh	0.16	P/FCF	-	EPS past 3/5Y	- -	ROIC	147.54%	52W Low	0.55 8.85%	Perf 3Y	-94.98%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	81.61% -	Gross Margin	-89.96%	Volatility	6.72% 6.45%	Perf 5Y	-97.78%
Dividend TTM	-	EV/Sales	19.65	EPS Y/Y TTM	173.40%	Oper. Margin	-1801.05%	ATR (14)	0.04	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.37	Sales Y/Y TTM	-33.92%	Profit Margin	3635.17%	RSI (14)	46.27	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.37	EPS Q/Q	112.86%	SMA20	-2.63%	Beta	1.09	Target Price	11.50
Payout	0.00%	Debt/Eq	0.20	Sales Q/Q	-99.21%	SMA50	-8.12%	Rel Volume	1.63	Prev Close	0.55
Employees	39	LT Debt/Eq	0.04	Earnings	May 15 BMO	SMA200	-25.14%	Avg Volume	155.18K	Price	0.60
IPO	Apr 28, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	- -20.00%	Trades		Volume	252,563	Change	8.01%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-30-21	Initiated	Cantor Fitzgerald	Overweight	$8
Nov-05-20	Initiated	Ascendiant Capital Markets	Buy	$5
Jun-28-18	Initiated	Maxim Group	Buy	$5

Jun-24-25 08:01AM	PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing (PR Newswire)
Jun-18-25 12:01PM	Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test (PR Newswire)
Jun-04-25 08:41AM	PAVmed subsidiary Veris Health partners with Ohio State University cancer center (TipRanks)
Jun-03-25 08:31AM	PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (PR Newswire)
May-27-25 07:31AM	Lucid Diagnostics to Join Russell 2000 and Russell 3000 Indexes (PR Newswire)
08:01AM	Loading…
May-15-25 08:01AM	PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results (PR Newswire) -13.72%
May-14-25 08:01AM	Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results (PR Newswire)
May-01-25 08:31AM	PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025 (PR Newswire) +13.17%
Apr-30-25 08:31AM	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025 (PR Newswire)
Apr-28-25 12:00PM	PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know (Zacks) -5.26%
Apr-24-25 08:01AM	NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard Esophageal DNA Test in Patients Without Symptomatic GERD (PR Newswire)
Apr-11-25 09:23AM	Lucid Diagnostics Announces Closing of Public Offering of Common Stock (PR Newswire)
Apr-09-25 07:24PM	Lucid Diagnostics Announces Pricing of Public Offering of Common Stock (PR Newswire) +15.21%
04:01PM	Lucid Diagnostics Announces Proposed Public Offering of Common Stock (PR Newswire)
Apr-03-25 09:00AM	Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference (PR Newswire)
08:01AM	Loading…
Mar-27-25 08:01AM	Lucid Diagnostics Launches 'Embrace the Future' Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology (PR Newswire) -5.77%
Mar-25-25 11:08AM	PAVmed Inc. (PAVM) Q4 2024 Earnings Call Transcript (SeekingAlpha) -5.06%
08:01AM	PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Mar-24-25 08:01AM	Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Mar-20-25 08:31AM	Lucid Diagnostics Announces Updated National Comprehensive Cancer Network (NCCN) Guidelines Now Include Esophageal Precancer Screening (PR Newswire)
Mar-18-25 08:31AM	Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard Esophageal Precancer Testing Accepted for Peer-Reviewed Publication (PR Newswire)
Mar-13-25 07:36AM	Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard Esophageal DNA Test (PR Newswire)
Mar-11-25 09:01AM	PAVmed to Hold a Business Update Conference Call and Webcast on March 25, 2025 (PR Newswire)
Mar-10-25 09:01AM	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025 (PR Newswire)
Mar-05-25 04:45PM	Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering (PR Newswire)
Mar-04-25 08:25AM	Lucid Diagnostics Announces $15.3 Million Registered Direct Offering (PR Newswire)
Feb-27-25 08:31AM	Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard in At-Risk Patients without Symptomatic GERD (PR Newswire) +10.00%
Feb-25-25 08:31AM	Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
Feb-24-25 08:31AM	PAVmed and Subsidiary Veris Health Complete Private Placement Financing (PR Newswire)
Feb-20-25 08:31AM	Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health (PR Newswire)
08:30AM	Loading…
Feb-18-25 08:30AM	PAVmed Regains Compliance with Nasdaq Stockholders' Equity Requirement (PR Newswire) +6.08%
Feb-06-25 08:57AM	Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (PR Newswire)
Jan-13-25 07:56AM	Lucid Diagnostics Announces Record Quarterly EsoGuard Test Volume (PR Newswire)
Dec-23-24 08:01AM	Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule (PR Newswire) +10.82%
Dec-19-24 08:01AM	Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters (PR Newswire)
Dec-11-24 08:01AM	Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard Esophageal DNA Test Accepted for Peer-Reviewed Publication (PR Newswire)
Dec-03-24 08:01AM	Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones (PR Newswire) +6.31%
Nov-20-24 07:56AM	Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard Esophageal DNA Test (PR Newswire)
Nov-18-24 08:15AM	Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum (PR Newswire) -10.53%
Nov-14-24 08:01AM	PAVmed Provides Business Update and Third Quarter 2024 Financial Results (PR Newswire) +6.86%
Nov-13-24 08:01AM	Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results (PR Newswire) -8.93%
Nov-07-24 08:01AM	Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing Accepted for Peer-Reviewed Publication (PR Newswire)
Nov-05-24 08:01AM	Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers (PR Newswire)
Oct-31-24 08:31AM	PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024 (PR Newswire)
Oct-30-24 08:31AM	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024 (PR Newswire)
Oct-15-24 07:51AM	Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test (PR Newswire) -8.18%
Oct-10-24 07:51AM	PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care (PR Newswire) -6.40%
Oct-09-24 08:01AM	Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit (PR Newswire)
Oct-08-24 07:49AM	Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024 (PR Newswire)
Oct-01-24 08:01AM	Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players (PR Newswire) +8.13%
Sep-24-24 08:01AM	American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test (PR Newswire)
Sep-16-24 04:30PM	PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements (PR Newswire)
Sep-10-24 07:56AM	Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress (PR Newswire) +43.70%
Sep-03-24 07:51AM	Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health (PR Newswire) +30.42%
Aug-20-24 08:16AM	Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard for Early Detection of Esophageal Precancer and Cancer (PR Newswire)
Aug-13-24 08:16AM	The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard to Enhance Early Detection of Esophageal Cancer (PR Newswire) -7.50%
08:01AM	PAVmed Provides Business Update and Second Quarter 2024 Financial Results (PR Newswire)
Aug-12-24 08:07AM	Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results (PR Newswire)
Aug-08-24 08:31AM	Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard #CheckYourFoodTube Precancer Testing Event (PR Newswire)
Aug-06-24 08:15AM	Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard Esophageal Precancer Testing (PR Newswire)
Aug-05-24 08:15AM	Lucid Diagnostics to Participate in Upcoming Investor Conferences (PR Newswire)
Jul-30-24 08:15AM	PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024 (PR Newswire) -15.84%
Jul-29-24 08:15AM	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024 (PR Newswire)
Jul-23-24 08:01AM	Lucid Diagnostics Announces Record Quarterly EsoGuard Test Volume (PR Newswire)
Jul-11-24 08:31AM	Lucid Diagnostics Launches New Corporate Website (PR Newswire)
Jul-02-24 07:55AM	Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing in a Screening Population (PR Newswire) -7.07%
Jun-13-24 07:58AM	PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (PR Newswire) +5.71%
Jun-12-24 08:05AM	4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard Esophageal Precancer Testing (PR Newswire) -9.48%
May-14-24 08:21AM	Lucid Diagnostics Inc. (NASDAQ:LUCD) Q1 2024 Earnings Call Transcript (Insider Monkey) +15.62%
07:53AM	PAVM Stock Earnings: PAVmed Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
May-13-24 08:43PM	PAVmed Provides Business Update and First Quarter 2024 Financial Results (PR Newswire) -9.43%
08:00AM	Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results (PR Newswire)
May-09-24 07:49AM	Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall (PR Newswire)
May-07-24 07:39AM	Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors (PR Newswire)
May-03-24 08:35AM	PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024 (PR Newswire) -7.59%
May-02-24 08:35AM	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024 (PR Newswire)
07:49AM	Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing (PR Newswire)
Apr-30-24 07:35AM	PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (PR Newswire) +16.96%
Apr-29-24 08:47AM	Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month (PR Newswire)
Apr-10-24 06:15PM	Why PAVmed Inc. (PAVM) Dipped More Than Broader Market Today (Zacks)
Apr-08-24 08:30AM	Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-28-24 09:47AM	PAVmed Inc. (NASDAQ:PAVM) Q4 2023 Earnings Call Transcript (Insider Monkey) -21.61%
Mar-27-24 12:35PM	Lucid Diagnostics Inc. (NASDAQ:LUCD) Q4 2023 Earnings Call Transcript (Insider Monkey) +32.52%
05:52AM	PAVM Stock Earnings: PAVmed Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
Mar-26-24 07:32PM	PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results (PR Newswire) -6.79%
Mar-25-24 05:30PM	Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Mar-21-24 09:30AM	Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard Esophageal Precancer Testing in a Screening Population (PR Newswire)
08:30AM	PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX (PR Newswire)
Mar-20-24 08:30AM	Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference (PR Newswire) +7.80%
Mar-13-24 08:30AM	PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024 (PR Newswire) -13.60%
Mar-12-24 08:30AM	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024 (PR Newswire) +10.13%
Feb-16-24 05:00PM	Lucid Diagnostics Provides Update Regarding World Trade Center Health Program (PR Newswire) +12.82% -11.82%
Feb-15-24 07:45AM	Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck Esophageal Cell Collection Device during Congressional Testimony (PR Newswire)
Feb-08-24 07:45AM	Lucid Diagnostics Executes Contract to Provide EsoGuard Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors (PR Newswire)
Dec-12-23 08:30AM	Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies (PR Newswire) +24.84%
Dec-11-23 09:00AM	PAVmed Provides Additional Details for Upcoming Stock Dividend to Shareholders (PR Newswire)
Dec-05-23 08:55AM	Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential (InvestorPlace) -19.35%
Dec-04-23 04:20PM	PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split (PR Newswire)
Dec-01-23 10:00AM	Top Penny Stocks for Q4 2023 (Investopedia)
Nov-20-23 12:44PM	PAVmed Inc. (NASDAQ:PAVM) Q3 2023 Earnings Call Transcript (Insider Monkey)

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
JAMES L. COX	Director	Dec 12 '24	Proposed Sale	0.78	9,469	7,380	Dec 12 05:19 PM
JAMES L. COX	Director	Dec 09 '24	Proposed Sale	0.86	38,095	32,739	Dec 09 05:21 PM
JAMES L. COX	Director	Dec 06 '24	Proposed Sale	1.00	15,600	15,627	Dec 06 05:58 PM
JAMES L. COX	Director	Dec 05 '24	Proposed Sale	1.01	1,836	1,854	Dec 05 05:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PAVM

PAVmed Inc

Upgrade your FINVIZ experience